

Information on COVID-19

Dear Customer,

The recent outbreak of the coronavirus (COVID-19) has the potential to impact on all our business and private activities in the period ahead.

Novo Nordisk Pharmatech's 1st priority is the safety and well-being of employees and all our stakeholders. To this end, Novo Nordisk Pharmatech has instigated its crisis management team to lead the response to this developing and unpredictable situation.

Measures include and are not limited to, following guidelines from health authorities in relation to hygiene at all locations, reducing travel to solely business critical matters. Novo Nordisk Pharmatech continues to carefully review the advice published by the local health authorities and we will adapt our approach accordingly.

Novo Nordisk Pharmatech has an existing business continuity plan designed to ensure ongoing, safe operations in case the site is affected by the presence of the coronavirus or other incident.

Novo Nordisk Pharmatech is continuously reviewing the likely impact upon its supply chain if product availability is affected by the consequences of the coronavirus. Presently, we conclude that the impact on current product portfolio is very limited. We will keep our customers informed of developments that might affect product supply and demand if the situation changes.

Your regular Novo Nordisk Pharmatech contacts are happy to discuss both your normal, as well as special requirements.

We sincerely hope that you and your families stay healthy and well.

Kind Regards



Gernot Stadlmann
Sales Director